Harlingene Life Sciences LLC

Harlingene Life Sciences LLC is a for-profit limited liability company registered in SAM.gov, located in Doylestown, Pennsylvania, with a registration set to expire on February 11, 2026. The company appears to be focused on pharmaceutical research and development, specifically targeting viral hepatitis treatments through innovative molecular approaches. Harlingene specializes in developing hepatoselective dihydroquinolizinone (HS-DHQ) molecules designed to address viral infections, with a particular emphasis on creating targeted antiviral therapies that minimize systemic side effects.

The company has been awarded multiple federal grants from the National Institute of Allergy and Infectious Diseases (NIAID) for advanced research into hepatitis treatments. These grants, ranging from Phase I to Phase II, focus on developing novel molecular compounds to treat and potentially prevent Hepatitis A and Hepatitis B virus infections. Specifically, Harlingene's research targets host RNA quality control enzymes (TENT4A/B or PAPD7/5) to suppress viral RNA synthesis, with a unique approach of creating liver-selective compounds that minimize neurotoxicity risks. Their research involves sophisticated molecular design strategies, including developing bis-carboxylic acid based derivatives with organic anion transporting polypeptide (OATP) substrate properties to achieve selective liver distribution. The grants, awarded between 2022 and 2023, have project completion dates extending to July 2027, indicating a substantial commitment to advancing these innovative antiviral therapeutic strategies.